TCGA-BH-A0AZ-01A-21R-A12P-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 64
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.630
- COAGULATION+0.500
- HEDGEHOG_SIGNALING+0.470
- TGF_BETA_SIGNALING+0.470
- UV_RESPONSE_DN+0.440
- NOTCH_SIGNALING+0.420
- ANGIOGENESIS+0.410
- KRAS_SIGNALING_UP+0.400
- MYOGENESIS+0.390
- APICAL_JUNCTION+0.360
Top 10 suppressed
- E2F_TARGETS-0.620
- MYC_TARGETS_V2-0.610
- G2M_CHECKPOINT-0.560
- MYC_TARGETS_V1-0.540
- DNA_REPAIR-0.390
- MTORC1_SIGNALING-0.370
- UNFOLDED_PROTEIN_RESPONSE-0.320
- OXIDATIVE_PHOSPHORYLATION-0.230
- PI3K_AKT_MTOR_SIGNALING-0.230
- MITOTIC_SPINDLE-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0DV-01A-21R-A12P-07 | — | A | 0.961 |
| 2 | TCGA-75-7030-01A-11R-1949-07 | — | cohortA1 | 0.937 |
| 3 | 4c7083b3-eccc-4d80-a31d-6fd3cd0222b4 | — | — | 0.934 |
| 4 | TCGA-BH-A0DI-01A-21R-A12P-07 | — | A | 0.922 |
| 5 | SRR8518203 | — | A | 0.922 |
| 6 | TCGA-CN-6016-01A-11R-1686-07 | — | — | 0.922 |
| 7 | TCGA-K4-A4AB-01B-12R-A28M-07 | — | — | 0.919 |
| 8 | TCGA-BH-A208-01A-11R-A157-07 | — | A | 0.917 |
| 9 | C3L-02552 | — | cohortSQ1 | 0.916 |
| 10 | TCGA-BH-A0DP-01A-21R-A056-07 | — | A | 0.913 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.630 | Inavolisib | — uncovered |
| COAGULATION | 0.500 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.470 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.470 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.440 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.420 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.410 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| MYOGENESIS | 0.390 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.360 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.330 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.330 | Inavolisib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.210 | Idelalisib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.170 | Inavolisib | — uncovered |